Diterpene alkaloid bulleyaconitine A as well as preparation method, pharmaceutical composition and application thereof
By extracting and preparing C19 diterpene alkaloid saccharin from aconite, the problem of major side effects of existing antidepressants was solved, and the significant antidepressant activity in the mouse model was achieved, and a new anti-depressant activity was provided. Depression drug development programs are superior to traditional drugs.
Patent Information
- Application Number
- CN202411066528.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-05
AI Technical Summary
Existing antidepressants have great side effects and have certain limitations in clinical applications. They cannot effectively solve the impact of high-intensity and high-stress life on people's physical and mental health, especially the poor treatment effect of depression.
C19 diterpene alkaloid samotosin was extracted and prepared from traditional Chinese medicine aconite, and used in the development of antidepressant drugs through specific preparation methods and pharmaceutical compositions.
Grassin showed significant antidepressant activity in mouse behavior despair model experiments, which was better than the positive drug fluoxetine. It provides a high-purity extraction method with simple operation and good reproducibility, and can be used to develop new Antidepressant drugs to reduce side effects.
Smart Images

Figure BDA0004979501740000011 
Figure BDA0004979501740000091 
Figure BDA0004979501740000111
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and more specifically, relates to a C 19 A type diterpene alkaloid aconitine A, a preparation method, a pharmaceutical composition and an application in antidepressant drugs. Background Art
[0002] Nowadays, social competition is becoming increasingly fierce. High-intensity and high-pressure life has a serious impact on people's physical and mental health. Depression is gradually increasing and seriously affects people's normal work and life. At present, drugs for treating depression generally have large side effects and have certain limitations in clinical application.
[0003] The inventors prepared Bulleyaconitine A from the traditional Chinese medicine Aconite and found that it showed significant antidepressant activity in a mouse behavioral despair model experiment, which was significantly better than the positive drug Fluoxetine and can be used to develop antidepressant drugs. Summary of the invention
[0004] In view of the shortcomings of the prior art, the present invention provides a diterpene alkaloid aconitine (specifically C 19 A type diterpene alkaloid aconitine) and its preparation method, pharmaceutical composition and application in antidepressant drugs.
[0005] To achieve the above object, the technical solution of the present invention is as follows:
[0006] A diterpene alkaloid aconitine A, which has a structure shown in the following formula (1):
[0007]
[0008] It should be noted that the diterpene alkaloid aconitine A may be a compound, stereoisomer, tautomer or pharmaceutically acceptable salt including the structure shown in formula (1). That is, the compound including the structure shown in formula (1), and its stereoisomer, tautomer and pharmaceutically acceptable salt are all within the protection scope of this application.
[0009] Another aspect of the present invention provides a method for preparing the diterpene alkaloid aconitone A, wherein the diterpene alkaloid aconitone A is extracted and separated from aconite root.
[0010] In the above technical scheme, the preparation method of the diterpene alkaloid aconitine A comprises the following steps:
[0011] S1. Take dried aconite root, add solvent to reflux and extract, combine the extracts and concentrate to obtain an extract;
[0012] S2, adding the extract to dilute hydrochloric acid to fully dissolve and suspend, filtering and removing impurities to obtain an acid aqueous solution;
[0013] Extracting the acid aqueous solution once with dichloromethane, filtering out the extract once, and obtaining a filtered acid aqueous solution;
[0014] The pH of the filtered acid aqueous solution is adjusted to be alkaline; and then secondary extraction is performed with dichloromethane to obtain a secondary extract;
[0015] S3, gradient eluting the secondary extract using a dichloromethane-methanol solution to obtain a fraction B;
[0016] When using silica gel thin layer analysis, the Rf value corresponding to fraction B is 0.76-0.80;
[0017] S4, gradient eluting fraction B using a methanol-water mixed solution to obtain fraction B4;
[0018] When using silica gel thin layer analysis, the Rf value corresponding to fraction B4 was 0.61-0.69;
[0019] S5, gradient eluting fraction B4 with methanol-water solution to obtain fraction L2;
[0020] When using silica gel thin layer analysis, the Rf value corresponding to fraction L2 was 0.53-0.65;
[0021] S6, separating the diterpene alkaloid aconitine A from fraction L2 using RP-HPLC (i.e., reverse phase high performance liquid chromatography);
[0022] The mobile phase used in the RP-HPLC method was a mixed solution of acetonitrile and water.
[0023] Furthermore, in step S2, the filtered acid aqueous solution is adjusted to a pH of 8-11 with sodium hydroxide; preferably, the pH is adjusted to 9.
[0024] Furthermore, in step S2, the extract is added into 8-15 times the mass of dilute hydrochloric acid to be fully dissolved and suspended, and then filtered to remove impurities to obtain an acid aqueous solution.
[0025] Furthermore, the concentration of the dilute hydrochloric acid is 0.1-1.0%, preferably 0.5%.
[0026] Further, in step S3, the secondary extract is separated by silica gel column chromatography to obtain fraction B; based on the total volume of 100, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution when fraction B is eluted (i.e. corresponding to fraction B) is (97:3)-(93:7); preferably, the volume ratio of dichloromethane to methanol is 95:5.
[0027] Furthermore, in step S4, the fraction B is separated by ODS column chromatography to obtain fraction B4; the volume ratio of methanol to water in the methanol-water mixed solution when fraction B4 is washed out (i.e., corresponding to fraction B4) is (45:55)-(55:45); preferably, the volume ratio of methanol to water is 50:50.
[0028] Furthermore, in step S4, the methanol-water mixed solution contains 0.01-1.1V% formic acid.
[0029] Preferably, in step S4, the methanol-water mixed solution contains 0.05V% formic acid.
[0030] Further, in step S5, the fraction B4 is separated by gel column chromatography to obtain fraction L2; based on the total volume of 100, the volume ratio of methanol to water in the methanol-water solution when fraction L2 is eluted (i.e., corresponding to fraction L2) is (25:75)-(35:65); preferably, the volume ratio of methanol to water is 30:70.
[0031] Further, in step S6, the volume ratio of acetonitrile to water in the acetonitrile-water mixed solution is (40:60)-(45:55); and the acetonitrile-water mixed solution contains 0.01-0.5V% trifluoroacetic acid.
[0032] Preferably, in step S6, the volume ratio of acetonitrile to water in the acetonitrile-water mixed solution is 43:57.
[0033] Preferably, in step S6, the acetonitrile-water mixed solution contains 0.1V% trifluoroacetic acid.
[0034] Furthermore, in step S1, the solvent is 88-98V% ethanol aqueous solution, the mass of the added solvent is 8-10 times that of the aconite root, the number of reflux extractions is 2-4 times, and each extraction takes 1-3 hours.
[0035] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned diterpene alkaloid aconitine.
[0036] Furthermore, the pharmaceutical composition also includes a pharmacodynamically acceptable carrier or excipient.
[0037] Furthermore, the pharmaceutical composition also includes a synergist, which is one or more of the following substances: fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram, venlafaxine, duloxetine, mirtazapine, bupropion, agomelatine, trazodone, reboxetine, imipramine, amitriptyline, clomipramine, doxepin, maprotiline, moclobemide, Shugan Jieyu Capsule, St. John's wort extract, flupentixol-melitracen, etc.
[0038] That is, the pharmaceutical composition containing the aconitine A of the present invention as an active ingredient and conventional pharmaceutical excipients or adjuvants or carriers is also included in the present invention.
[0039] Furthermore, the dosage form of the pharmaceutical composition is tablets, capsules, granules, oral liquid, granules, pills or micropills.
[0040] In another aspect, the present invention also provides the above-mentioned C 19 Application of type diterpene alkaloid aconitine or the above-mentioned pharmaceutical composition in antidepressant drugs.
[0041] Compared with the prior art, the present invention has the following advantages:
[0042] (1) The experimental results show that the C 19 The diterpene alkaloid aconitine A showed significant antidepressant activity in the mouse behavioral despair model tail suspension test, which was better than the positive drug fluoxetine and can be used to develop antidepressant drugs;
[0043] (2) The present invention provides C 19 The preparation method of the diterpene alkaloid aconitine A can be obtained by extracting C from aconite root with simple operation, good reproducibility and high extraction purity. 19 Type diterpene alkaloid aconitone. DETAILED DESCRIPTION
[0044] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments.
[0045] It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention.
[0046] In the examples, unless otherwise specified, all the means used are conventional means in the art.
[0047] As used herein, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, step, method, article, or apparatus that comprises the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, step, method, article, or apparatus.
[0048] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0049] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0050] In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0051] Example 1
[0052] This embodiment discloses a C 19 A method for preparing aconitine A type diterpene alkaloid, wherein the C 19 The diterpene alkaloid aconitone A was extracted and separated from Aconitum carmichaelii.
[0053] The C 19 The preparation method of the diterpene alkaloid aconitine A comprises the following steps:
[0054] S1. Take dried aconite root, add solvent to reflux and extract, combine the extracts and concentrate to obtain an extract;
[0055] Specifically, take dried aconite root and 95% ethanol aqueous solution with a mass 10 times that of aconite root as solvent, reflux extract three times, each extraction for 2 hours, combine the extracts and concentrate to obtain an extract;
[0056] S2. Add the extract to dilute hydrochloric acid to fully dissolve and suspend it, filter and remove impurities to obtain an acid aqueous solution; extract the acid aqueous solution once with dichloromethane, filter out the primary extract, and obtain a filtered acid aqueous solution; adjust the pH of the filtered acid aqueous solution to alkaline; and then perform a secondary extraction with dichloromethane to obtain a secondary extract.
[0057] Specifically, the extract is added to 10 times the mass of 0.5% dilute hydrochloric acid to fully dissolve and suspend, and then filtered to remove impurities, and the filtered acid aqueous solution is extracted three times with 1.5 times the volume of dichloromethane to obtain an acidified dichloromethane extract (one-time extract, discarded) and an acid water layer, and the acid water layer is the filtered acid aqueous solution;
[0058] The filtered acid aqueous solution is adjusted to a pH of 8-11 with sodium hydroxide; preferably, the pH is adjusted to 9; and then extracted twice with dichloromethane, this time with dichloromethane.
[0059] S3. The secondary extract is subjected to gradient elution using a dichloromethane-methanol solution to obtain fraction B; when detected by silica gel thin layer, the brick-red spot of potassium bismuth iodide reagent corresponding to fraction B has an Rf value of 0.76-0.80. Specifically, the secondary extract is separated by silica gel column chromatography to obtain fraction B; based on the total volume of 100, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution when fraction B is eluted is (97:3)-(93:7).
[0060] Preferably in this embodiment, the secondary extract is subjected to silica gel column chromatography, using dichloromethane-methanol gradient elution with a volume ratio of 100:0, 95:5, 92:8, 90:10, 85:15, 75:25, 65:35, 50:50, and 0:100 to obtain fractions 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, and 81-90, for a total of 90 fractions.
[0061] Then, using silica gel thin layer detection, according to the brick red spots shown by potassium bismuth iodide reagent, the Rf values were observed to be 0.82-0.86 (fractions 1-10), 0.76-0.80 (fractions 11-20), 0.72-0.75 (fractions 21-30), 0.65-0.70 (fractions 31-40), 0.56-0.62 (fractions 41-50), 0.50-0.54 (fractions 51-60), 0.42-0.48 (fractions 61-70), 0.30-0.38 (fractions 71-80), 0.25-0.28 (fractions 81-90). Similar fractions were combined to obtain fractions A, B, C, D, E, F, G, H and I in turn. Among them, fractions 11-20 were combined to obtain fraction B.
[0062] S4. Fraction B is subjected to gradient elution using a methanol-water mixed solution to obtain fraction B4, wherein the methanol-water mixed solution contains 0.05V% formic acid. When detected by silica gel thin layer chromatography, the Rf value corresponding to fraction B4 is 0.61-0.69.
[0063] That is, according to the brick red spots revealed by the bismuth potassium iodide reagent and the characteristic ultraviolet absorption (λ max =230nm) Fraction B was selected for the next separation.
[0064] Specifically, fraction B is separated by ODS column chromatography to obtain fraction B4; the volume ratio of methanol to water in the methanol-water mixed solution when fraction B4 is washed out (i.e., corresponding to fraction B4) is (45:55)-(55:45). The methanol-water mixed solution contains 0.01-1.1V% formic acid.
[0065] In this embodiment, preferably, a methanol-water mixed solution (methanol-water mixed solution containing 0.05V% formic acid) with a volume ratio of 20:80, 30:70, 40:60, 50:50, 60:40, 80:20, 100:0 is used for gradient elution. Then, fractions 1-6, 7-15, 16-23, 24-36, 37-45, 46-57, 58-68 are obtained in sequence, and a total of 68 fractions are collected.
[0066] Using silica gel thin layer chromatography, according to the brick red spots shown by potassium bismuth iodide reagent, the Rf values were observed to be 0.35-0.44 (fractions 1-6), 0.45-0.49 (fractions 7-15), 0.50-0.60 (fractions 16-23), 0.61-0.69 (fractions 24-36), 0.70-0.74 (fractions 37-45), 0.75-0.79 (fractions 46-57), 0.80-0.89 (fractions 58-68). Similar fractions were combined into 7 fractions B1 to B7. Among them, fractions 24-36 were combined to obtain fraction B4. The Rf value of fraction B4 was 0.61-0.69.
[0067] S5. Fraction B4 is subjected to gradient elution using a methanol-water solution to obtain fraction L2. When detected by silica gel thin layer chromatography, the Rf value of fraction L2 is 0.53-0.65.
[0068] According to the brick-red spots revealed by potassium bismuth iodide reagent and the characteristic ultraviolet absorption (λ max =230nm) select fraction B4 for the next separation. Fraction B4 is separated by gel column chromatography to obtain fraction L2; based on the total volume of 100, the volume ratio of methanol to water in the methanol-water solution when fraction L2 is eluted is (25:75)-(35:65).
[0069] The specific operation of this embodiment includes: subjecting fraction B4 to gel column chromatography, using methanol-water gradient elution with a volume ratio of 0:100, 30:70, 70:30, and 100:0, and collecting fractions 1-6, 7-15, 16-21, and 22-25 in sequence. After collecting a total of 25 fractions, silica gel thin layer chromatography is used for identification. According to the brick-red spots shown by potassium bismuth iodide reagent, the Rf values are observed to be 0.35-0.52 (fraction 1-6), 0.53-0.65 (fraction 7-15), 0.66-0.75 (fraction 16-21), and 0.75-0.85 (fraction 22-25), respectively. Similar fractions are combined into 4 fractions L1 to L4; fractions 7-15 are combined to obtain fraction L2.
[0070] S6, using RP-HPLC (i.e., reverse phase high performance liquid chromatography) to separate C from fraction L2 19The invention discloses a type of diterpene alkaloid aconitine (compound 1); the mobile phase used in the RP-HPLC method is an acetonitrile-water mixed solution; the volume ratio of acetonitrile to water in the acetonitrile-water mixed solution is (40:60)-(45:55); and the acetonitrile-water mixed solution contains 0.01-0.5V% trifluoroacetic acid.
[0071] Specifically, the brick-red spots revealed by the bismuth potassium iodide reagent and the characteristic ultraviolet absorption (λ max =230nm) fraction L2 was selected for the next separation. The mobile phase used in the RP-HPLC separation of fraction L2 had a volume ratio of acetonitrile to water of 43:57, and the acetonitrile-water mixed solution contained 0.1V% trifluoroacetic acid. 18 The chromatographic column was prepared in fraction L2 to obtain C 19 Aconitone A (t R =22.5min, purity 98%).
[0072] The physical properties and test data of the compound 1 prepared in this Example 1 are as follows:
[0073] White amorphous powder, easily soluble in methanol. High resolution mass spectrometry (HR-ESI-MS) m / z 644.3396 ([M+H] + The calculated value is 644.3429), and combined with NMR data, its molecular formula is determined to be C 35 H 49 NO 10 , its unsaturation is calculated to be 12, and the NMR data are as follows:
[0074] 1 H NMR (400 MHz, CDCl 3 )δ:8.01(2H,d,J=8.4Hz,H-2”,6”),6.92(2H,d,J=8.4Hz,H-3”,5”),4.87(1H,d,J=5.0Hz,H-14β),3.97(1H,d,J=6.8Hz,H-6β),3.85(3H,s,4”-OCH 3 ),3.59(1H,d,J=8.4Hz,H-18),3.52,3.27,3.25,3.14(each3H,s,4×OCH 3 ),3.38(1H,dd,J=8.8,6.0Hz,H-16),1.33(3H,s,H-2'),1.09(3H,t,J=7.2Hz,H-21);
[0075] 13 C NMR (100 MHz, CDCl 3)δ:169.9(C-1'),163.3(C-4”),166.1(C-7”),131.7(C-2”,6”),122.7(C-1”),113.7(C-3”,5”),85.7(C- 8),85.1(C-1),83.6(C-16),83.0(C-6),78.6(C-14),78.5(C-18),74.9(C-13),62.0(C-17),59.1(18-OCH 3 ),58.8(16-OCH 3 ),57.8(6-OCH 3 ),56.3(1-OCH 3 ),55.4(4”-OCH 3 ),53.6(C-19),50.3(C-11),49.5(C-5),49.1(C-7),49.1(C-20),45.2(C-9),41.0(C-10) ,39.3(C-15),39.2(C-4),35.8(C-3),34.9(C-12),26.4(C-2),21.7(C-2'),13.6(C-21).
[0076] The C 19 The structural formula of the diterpene alkaloid aconitone A is shown below:
[0077]
[0078] Comparative Example 1
[0079] Comparative Example 1 of the present invention provides C 19 The method for preparing the type diterpene alkaloid aconitine A has similar steps to those of Example 1, except that in step S6, the mobile phase used in separating fraction L2 by RP-HPLC does not contain trifluoroacetic acid.
[0080] The compound prepared in Comparative Example 1 had severe peak tailing during the preparation process. Liquid phase analysis after preparation revealed that it contained a large amount of impurities. The purity of the prepared compound 1 was less than 50%.
[0081] Comparative Example 2
[0082] Comparative Example 2 of the present invention provides C 19 The preparation method of the diterpene alkaloid aconitine A is similar to that of Example 1, except that in step S4, when fraction B is separated by ODS column chromatography, a methanol-water solution with an initial volume ratio of 20:80 is used for elution. The methanol-water solution does not contain formic acid.
[0083] Comparative Example 2: This compound could not be detected during the subsequent fraction preparation process:
[0084] The results showed that compound 1 could not be prepared.
[0085] Test Example 1
[0086] This test example discloses the antidepressant effect of the above compound aconitine A in a mouse behavioral despair model experiment (the gold standard for antidepressant drug screening).
[0087] 1. Experimental materials and instruments
[0088] Fluoxetine hydrochloride was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; methyltaurine and norcoclaurine were purchased from Shanghai Standard Standard Technical Services Co., Ltd.; total alkaloids from Aconitum carmichaelii; and aconitine A.
[0089] ZIL-2 mouse self-activity box (Shanghai Xinman Science and Education Equipment Co., Ltd.); YLS-18A mouse tail suspension instrument (Anhui Zhenghua Biological Instrument Equipment Co., Ltd.); electronic balance (Sartorius Scientific Instrument (Beijing) Co., Ltd.).
[0090] 2. Experimental Animals
[0091] ICR mice, male, weighing 18-22g, SPF grade, provided by Weitong Lihua, animal license number: SYXK (Beijing) 2023-0001. The animals were kept in an environment with a temperature of 23±2℃ and a humidity of 50±10%, and the lighting time was 12h per day (lighting from 7:00 to 19:00). The experiments were carried out after the animals were raised for 3 days. They were fasted for 6h before the start of the behavioral experiment and had free access to water.
[0092] 3. Experimental Methods
[0093] 70 ICR male mice were divided into 7 groups according to the descending order of the number of spontaneous activities of the animals, namely, blank group (same volume of normal saline), positive drug fluoxetine group (10 mg / kg), methyltaurine group (10 mg / kg), higenamine group (10 mg / kg), total alkaloids of aconitum group (10 mg / kg), low-dose aconitine group (0.03 mg / kg), high-dose aconitine group (0.3 mg / kg), 10 mice in each group, numbered respectively. All drugs were added to normal saline to make a solution, and each group was gavaged once a day, with a volume of 0.1 ml / 10 g body weight. After continuous administration for 3 days, spontaneous activity experiments were performed on the 4th day, and tail suspension experiments were performed on the 5th day.
[0094] 3. Experimental results
[0095] As shown in Table 1, compared with the blank group, the low and high dose groups of aconitine A (0.03 and 0.3 mg / kg) can significantly shorten the immobility time of mice in the tail suspension test, showing significant antidepressant activity, which is significantly better than the positive drugs fluoxetine (10 mg / kg, the first-line chemical drug for the clinical treatment of depression), methyltaurine (10 mg / kg), norhiazolin (10 mg / kg) and total alkaloids of Aconitum carmichaelii (10 mg / kg).
[0096] Table 1 Effects of aconitine A on the tail suspension immobility time of behavioral despair model mice
[0097]
[0098] (Compared with the blank group, *** P<0.001)
[0099] As shown in Table 2, compared with the blank group, each drug-treated group had no significant effect on the spontaneous activity of mice in the open field test, indicating that the effect of each drug-treated group on the immobility time of mice in the tail suspension test was not related to neural excitability.
[0100] Table 2 Effects of aconitine A on horizontal movement distance in the open field of behavioral despair model mice
[0101]
[0102]
[0103] In summary, the C 19 The diterpene alkaloid aconitine has antidepressant activity that is significantly superior to fluoxetine, a first-line drug for depression, and can be used as a drug precursor for the treatment of depression.
[0104] Application Example 1
[0105] The application example of the present invention discloses a capsule preparation using aconitine A as a raw material drug, and the components thereof are as follows:
[0106]
[0107] The specific preparation process is as follows:
[0108] Take aconitine A, starch and sodium metabisulfite and mix them evenly, add anhydrous ethanol to make a soft material, pass through a 24-mesh sieve, make granules, dry, add magnesium stearate, mix well, and put into capsules.
[0109] Application Example 2
[0110] The application example of the present invention discloses a granule preparation using the compound aconitine A as a raw material drug, and the components thereof are as follows:
[0111] Aconitone A 4.0mg
[0112] Starch 6.0g
[0113] Sodium bisulfite 0.2g
[0114] Magnesium stearate 0.2g
[0115] Anhydrous ethanol
[0116] Makes 100 bags.
[0117] The specific preparation process is as follows:
[0118] After mixing aconitine A with starch and sodium bisulfite, anhydrous ethanol is added to make a soft material, the mixture is passed through a 24-mesh sieve to form granules, the granules are dried, magnesium stearate is added, the mixture is mixed and the granules are bagged.
[0119] Application Example 3
[0120] The application example of the present invention discloses an oral liquid with the compound aconitine A as a raw material medicine, and its components are as follows:
[0121]
[0122] The specific preparation process is as follows:
[0123] After the above components are mixed evenly, they can be packaged using a conventional oral liquid preparation method.
[0124] Application Example 4
[0125] The application example of the present invention discloses an injection with the compound aconitine A as the raw material medicine, and its components are as follows:
[0126]
[0127] The specific preparation process is as follows:
[0128] After the above components are mixed evenly, 100 vials can be obtained using conventional preparation methods for injections.
[0129] Application Example 5
[0130] The application example of the present invention discloses a tablet with compound aconitine A and fluoxetine as raw materials, and its components are as follows:
[0131]
[0132] The specific preparation process is as follows:
[0133] Take aconitine A, fluoxetine, hydroxypropyl methylcellulose, talc, lactose and magnesium stearate and mix them evenly, add anhydrous ethanol to make a soft material, pass through a 24-mesh sieve, make granules, dry, add magnesium stearate, mix evenly and press into tablets.
[0134] Application Example 6
[0135] The application example of the present invention discloses a capsule preparation using the compound aconitine A and luyoutai as raw materials, and the components thereof are as follows:
[0136]
[0137]
[0138] The specific preparation process is as follows:
[0139] Take aconitine A, Luyoutai and sodium metabisulfite and mix them evenly, then add anhydrous ethanol to make a soft material, pass through a 24-mesh sieve to make granules, dry, add magnesium stearate, mix evenly and put into capsules.
[0140] Application Example 7
[0141] The application example of the present invention discloses an injection with compound aconitine A and paroxetine as raw materials, and its components are as follows:
[0142]
[0143] The specific preparation process is as follows:
[0144] After the above components are mixed evenly, 100 vials can be obtained using a conventional injection preparation method.
[0145] The above-mentioned embodiments only express several implementation modes of the present invention, and the description thereof is relatively specific and detailed, but it should not be understood as limiting the scope of the invention patent.
[0146] It should be noted that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention, and these modifications and improvements all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A diterpene alkaloid aconitine A, characterized in that It has the structure shown in formula (1):
2. The method for preparing the diterpene alkaloid aconitine A according to claim 1, characterized in that: The diterpene alkaloid aconitone A is extracted and separated from aconite root.
3. The preparation method according to claim 2, characterized in that: The following steps are involved: S1. Take dried aconite root, add solvent to reflux and extract, combine the extracts and concentrate to obtain an extract; S2, adding the extract to dilute hydrochloric acid to fully dissolve and suspend, filtering and removing impurities to obtain an acid aqueous solution; Extracting the acid aqueous solution once with dichloromethane, filtering out the extract once, and obtaining a filtered acid aqueous solution; The pH of the filtered acid aqueous solution is adjusted to be alkaline; and then secondary extraction is performed with dichloromethane to obtain a secondary extract; S3, gradient eluting the secondary extract using a dichloromethane-methanol solution to obtain a fraction B; When using silica gel thin layer analysis, the Rf value corresponding to fraction B is 0.76-0.80; S4, gradient eluting fraction B using a methanol-water mixed solution to obtain fraction B4; When using silica gel thin layer analysis, the Rf value corresponding to fraction B4 was 0.61-0.69; S5, gradient eluting fraction B4 with methanol-water solution to obtain fraction L2; When using silica gel thin layer analysis, the Rf value corresponding to fraction L2 was 0.53-0.65; S6, separating and obtaining the diterpene alkaloid aconitine A from fraction L2 by RP-HPLC method; The mobile phase used in the RP-HPLC method was a mixed solution of acetonitrile and water.
4. The preparation method according to claim 3, characterized in that: In step S2, the filtered acid aqueous solution is adjusted to a pH of 8-11 with sodium hydroxide.
5. The preparation method according to claim 3, characterized in that: In step S2, the filtered acid aqueous solution is adjusted to pH=9 with sodium hydroxide.
6. The preparation method according to claim 3, characterized in that: In step S2, the extract is added into 8-15 times the mass of dilute hydrochloric acid to fully dissolve and suspend, and then filtered to remove impurities to obtain an acid aqueous solution.
7. The preparation method according to claim 3, characterized in that: The concentration of the dilute hydrochloric acid is 0.1-1.0%.
8. The preparation method according to claim 3, characterized in that: The concentration of the dilute hydrochloric acid is 0.5%.
9. A pharmaceutical composition, characterized in that It comprises the diterpene alkaloid aconitine A described in claim 1.
10. Use of the diterpene alkaloid aconitine A according to claim 1 and / or the pharmaceutical composition according to claim 9 in antidepressant drugs.
Citation Information
Patent Citations
Preparation method of high purity bulleyaconitine A
CN101555227A
Method for preparing simplified high-purity bulleyaconitine A
CN101830849A
New C19 diterpenoid alkaloid in Aconitum hemsleyanum var. janyuanum and applications thereof in preparation of anticancer drugs
CN102977019A
Bulleyaconitine A efficient extraction and separation method
CN104326981A
Preparation method of bulleyaconitine A
CN115703740A
